Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily affects
the lining of the synovial joints and is associated with progressive disability, premature …

Background Serious infections are a major concern for patients considering treatments for
rheumatoid arthritis. Evidence is inconsistent as to whether biological drugs are associated …

Background: Low-dose glucocorticoids are frequently used for the management of
rheumatoid arthritis (RA) and other chronic conditions, but the safety of long-term use …

Because of their potent anti-inflammatory properties, corticosteroids have been used for
decades to treat many diseases, including rheumatic diseases. They are frequently used in …

Introduction: Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory
approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and …

RA is known to be associated with an increased risk of serious infection. Even more than 50
years ago, observational studies showed a greater than 2-fold increased risk of serious …

Monoclonal antibodies (mAbs) are now established as targeted therapies for malignancies,
transplant rejection, autoimmune and infectious diseases, as well as a range of new …

Objective To investigate the rate of serious bacterial, viral or opportunistic infection in
patients with rheumatoid arthritis (RA) starting tocilizumab (TCZ) versus tumour necrosis …

Epidemiology is the study of the distribution and determinants of disease in human
populations. Over the past decade there has been considerable progress in our …

Objectives. To evaluate the risk of serious infections (SIs) in patients with RA treated with
anti-TNF therapy with emphasis on the risk across different ages. Methods. Using data from …